雌激素及拮抗剂他莫昔芬在肝癌发生发展中的作用和分子机制的研究进展  

Research Progress on the Role and Molecular Mechanisms of Estrogen and Its Antagonist Tamoxifen in the Carcinogenesis and Development of Liver Cancer

作　　者：王宏阳 李学英[1,2] 潘有福 WANG Hongyang;LI Xueying;PAN Youfu(Department of Medical Genetics,Zunyi Medical University,Zunyi 563003,China;Key Laboratory of Gene Detection and Treatment in Guizhou Province,Zunyi 563003,China)

机构地区：[1]遵义医学院医学遗传学教研室,贵州遵义563003 [2]贵州省基因检测与治疗特色重点实验室,贵州遵义563003

出　　处：《医学综述》2018年第6期1077-1081,1086,共6页Medical Recapitulate

基　　金：国家自然科学基金(31760321);贵州省科技计划项目(黔科合基础[2017]1217);遵义医学院遗传学扶持学科建设项目(2012-2016)

摘　　要：目前越来越多的证据表明肝脏是激素敏感性器官,雌激素通过雌激素受体介导的信号转导途径发挥生理作用,同时也可能对肝癌的发生、发展有促进作用。他莫昔芬作为雌激素的拮抗剂,已广泛用于乳腺癌的治疗,但其用于治疗肝癌还处于探索阶段。目前已有一些他莫昔芬有益于患者的临床试验,他莫昔芬可能会使特定肝癌患者群体获益。他莫昔芬对于肝癌的治疗具有潜在的应用前景和临床价值,深入了解他莫昔芬在肝癌中发挥作用的分子机制可为临床治疗提供重要的理论依据。There is growing evidence showing that liver is a hormone sensitive organ.Estrogen,via the estrogen receptors-mediated signaling pathways,not only plays a physiological role,but also plays a role in the carcinogenesis and development of hepatocellular carcinoma.Being an antagonist of estrogen,tamoxifen has been widely used in the treatment of breast cancer,but its application in the treatment of liver cancer is still in the exploratory stage.Clinical trials show tamoxifen is beneficial to some liver cancer patients,implying that tamoxifen may benefit a specific population of patients with hepatocellular carcinoma.Tamoxifen has potential application and clinical value for the treatment of hepatocellular carcinoma,and further understanding of the molecular mechanism provides an important theoretical basis for the clinical treatment.

关 键 词：肝癌 雌激素 雌激素受体 他莫昔芬 拮抗剂 靶向治疗 

分 类 号：R735.7[医药卫生—肿瘤]